Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction.
This study was designed to determine the changes in the heart that result from inhibition of long-chain fatty acid oxidation with 2-tetradecylglycidic acid (TDGA). Male Sprague-Dawley rats (n = 64) were treated with TDGA (20 mg.kg-1.day-1) or a comparable volume of vehicle by gavage feeding for 7 or 21 days. In conscious rats TDGA produced no changes in heart rate, left ventricular systolic or end-diastolic pressures, left ventricular pressure development (dP/dt), or the time constant of left ventricular relaxation. Left ventricular developed pressure was not changed at 21 days. TDGA increased left ventricular weight, left ventricular weight-to-body weight ratio, and total heart weight-to-body weight ratio. Left ventricular endocardial and epicardial myocyte volumes were increased by 53 and 65%, respectively. Myocardial triglyceride content was increased threefold. Left ventricular chamber stiffness constants between end-diastolic pressures of 0 and 30 mmHg were increased, and left ventricular end-diastolic volumes at operating end-diastolic pressures were decreased at both 7 and 21 days. The myocardial stiffness constant was also increased at 7 and 21 days. Thus inhibition of long-chain fatty acid oxidation with TDGA increased left ventricular mass and altered left ventricular chamber and muscle stiffness without changing left ventricular relaxation or systolic function. We conclude that inhibition of long-chain fatty acid oxidation produced an unusual model of left ventricular hypertrophy and diastolic dysfunction characterized by abnormalities of passive-elastic properties but preserved relaxation.
Litwin
S E
SE
Department of Internal Medicine, Veterans Administration Medical Center, Tucson 85723.
Raya
T E
TE
Gay
R G
RG
Bedotto
J B
JB
Bahl
J J
JJ
Anderson
P G
PG
Goldman
S
S
Bressler
R
R
D000818:Animals; D006332:Cardiomegaly / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D004852:Epoxy Compounds / Q000494:pharmacology; D005227:Fatty Acids / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D006439:Hemodynamics; D008297:Male; D008854:Microscopy, Electron; D008955:Models, Cardiovascular; D009206:Myocardium / Q000473:pathology; D010084:Oxidation-Reduction; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D004852:Epoxy Compounds; D005227:Fatty Acids; C021756:2-tetradecylglycidic acid